TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01932502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobazam (Onfi)
Description: Subject's clonazepam will be converted to the following Onfi doses per day:~Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.~Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.~Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.~Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.~The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.~Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initial conversion and titration
Description: Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion schedule - Week 1
Description: The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion schedule - Week 2
Description: Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion schedule - Week 3
Description: Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
Study: NCT03458468

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Equivalent volume of saline prior to skin incision
Study: NCT03808194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditional lottery incentive
Description: Participants in the lottery incentive arm must fulfill the following criteria to be entered into the lottery. Participants must visit the clinic by month 1, initiate ART by month 3 and achieve viral suppression by month 6. Participants in this arm will be eligible to win the lottery.
Study: NCT03291392

Intervention type: GENETIC
Intervention: Gene expression or biomarkers exploration

Intervention type: GENETIC
Intervention: Gene expression or biomarkers exploration

Intervention type: GENETIC
Intervention: Gene expression or biomarkers exploration
Study: NCT03147443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized Decoction
Description: Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
Study: NCT03808194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized ART linkage package
Description: Optimized ART linkage package
Study: NCT03904407

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Lactobacillus Probiotic Placebo Capsule
Description: Lactobacillus Probiotic placebo capsules identical in appearance taken by mouth once daily for 4 weeks
Study: NCT03355586

Intervention type: COMBINATION_PRODUCT
Intervention: Electromagnetic navigation
Description: Electromagnetic navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
Study: NCT00724594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
Study: NCT04800211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Test Product 1
Description: Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)
Study: NCT00724594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Saline was given in the same volume, at the same timing as NAC infusions
Study: NCT01087944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-filled syringe
Description: Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
Study: NCT04800211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Test Product 2
Description: Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)
Study: NCT02195349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2831781
Description: GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2831781
Description: GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2831781
Description: GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
Study: NCT03147443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Decoction
Description: Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Individualized Decoction
Description: Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tested drug minus heat-clearing herbs
Description: It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
Study: NCT02180412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panhematin
Description: Glucose loading

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose is administered to both groups as routine care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Glucose is administered to both groups as routine care.
Study: NCT04078685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard catheter ablation
Description: Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contact Force-sensing-based catheter ablation
Description: Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
Study: NCT00973024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 3 mg
Description: JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 1 mg
Description: JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 6 mg/3mg
Description: JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443 10 mg
Description: JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
Study: NCT02195349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Commercial saline solution administered by IV over approximately 2 hours
Study: NCT00973024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
Study: NCT01907477

Intervention type: OTHER
Group type: OTHER
Intervention: Samples taken at the clinical hematology unit
Study: NCT02857478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987519, SPF 50, Y51-002
Description: Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987519, SPF 50, P04-147
Description: Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
Study: NCT03327610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VC-CMV20
Description: Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VC-CMV50
Description: Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PC-CMV1
Description: Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PC-CMV3
Description: Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSV10
Description: Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSV25
Description: Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
Study: NCT01391481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perfluorocarbon
Description: Vaporized PFC Inhalation 100ml/8h for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water for Injection
Description: Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
Study: NCT01486654

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation - Cathodal stimulation
Description: Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation - Anodal stimulation
Description: Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation - Sham stimulation
Description: Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
Study: NCT02195349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Commercial saline solution administered by IV over approximately 2 hours

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Commercial saline solution administered by IV over approximately 2 hours
Study: NCT02289872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruView PCD Video laryngoscope
Description: Video-Laryngoscopy
Study: NCT04173325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
Description: PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Injection [Camptosar]
Description: Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
Study: NCT00687830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol afternoon
Description: Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol morning
Description: Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
Study: NCT00698711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC-2-KLH
Description: The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.~After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient.
Study: NCT03908437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine/naloxone
Description: A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs
Study: NCT03391596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based ACT intervention
Description: The Internet-based ACT intervention is a 12-week program based on the processes of Acceptance and Commitment Therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized rehabilitation
Description: Standardized institutional rehabilitation in a rehabilitation center
Study: NCT02421588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (PM01183)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Study: NCT04292743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eryaspase
Description: intravenous administration of Eryaspase, starting dose 75 units/kg, dose escalation to 100 units/kg, dose reduction 50 units/kg and 25 units/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: intravenous administration of FOLFIRINOX
Study: NCT03391596

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Support by voluntary caregiver associations
Description: Support given by voluntary caregiver associations
Study: NCT02563938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK001
Description: Given parenterally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04077580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methenamine Hippurate 1000 MG
Description: Methenamine and placebo is taken 1 tablet morning and evening for 180 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methenamine Hippurate 1000 MG
Description: Methenamine and placebo is taken 1 tablet morning and evening for 180 days
Study: NCT02472704

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten challenge
Description: gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo challenge
Description: placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
Study: NCT00296140

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: self management of PSD symptoms

Intervention type: PROCEDURE
Group type: OTHER
Intervention: screening and treatment of PSD